Well the second quarter is over this week. In theory it's the strongest sales quarter for antivirals. We're looking at Inavir in particular and whether they have exceeded first quarter sales. No government contracts so I'm not expecting much from relenza. Inavir should however give us an insight into it's potential in the seasonal market.
